Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27782853 | 0.86 | LMNA (0.32) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL28906292 | 0.81 | LMNA (0.33) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL27272 | 0.81 | KDM4E (0.37) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL1684239 | 0.76 | KDM4E (0.37) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL1499965 | 0.75 | CA2 (0.36) | TSHRKDM4ECA2CA1 | |
| SCHEMBL28134578 | 0.74 | KDM4E (0.35) | KDM4E | |
| SCHEMBL29655023 | 0.74 | LMNA (0.34) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL28473411 | 0.73 | KDM4E (0.34) | KDM4E | |
| SCHEMBL7998472 | 0.73 | KDM4E (0.34) | KDM4E | |
| SCHEMBL28535571 | 0.73 | KDM4E (0.34) | LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | disclosed |
| US-8242098-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7488734-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090005351-A1 | Hormone replacement therapy | WYETH | 2009-01-01 | — | — | US | disclosed |
| US-20080152699-A1 | Method of treating menopausal women transdermally with testosterone | THE PROCTER & GAMBLE COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-7354915-B2 | 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-20080015170-A1 | Method of treating menopausal women transdermally with testosterone | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| EP-1857110-A2 | Hormone replacement therapy | Wyeth (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | WYETH | 2004-01-22 | — | — | US | disclosed |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000801-A2 | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000227-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000225-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF HORMONE-RELATED CONDITIONS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000230-A2 | CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND USE THEREOF FOR TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | disclosed |
| US-6455568-B2 | ADMINISTERING INDOLE DERIVATIVE DRUGS SUCH AS 2-(4-HYDROXY-PHENYL)-3-METHYL-1-(4-(2-PIPERIDIN-1-YL-ETHOXY)-BENZYL)-1H -INDOL-5-OL, AND ONE OR MORE ESTROGENS | WYETH | 2002-09-24 | — | — | US | disclosed |
| EP-0789080-A2 | Process for the preparation of organic aminium lactates and their use in the preparation of dilactide | Gesellschaft für ökologische Technologie und Systemanalyse e.V. (DE) | 1997-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | GPER1, OXTR, SHBG | LMNA 1457/4885CYP3A4 582/4885GABRA1 1844/4885 |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | SRD5A1, SRD5A2, OXER1 | LMNA 4693/4885CYP3A4 1165/4885GABRA1 4012/4885 |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | OXTR, GNRHR, SHBG | LMNA 1295/4885CYP3A4 467/4885GABRA1 2227/4885 |
| US-20040006060-A1 | Methods of treating hormone-related conditions using cyclothiocarbamate derivatives | ESRRA, GNRHR, ESRRG | LMNA 844/4885CYP3A4 2145/4885GABRA1 1126/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | LMNA 4353/4885CYP3A4 440/4885GABRA1 281/4885 |
| US-20040014798-A1 | Cyclothiocarbamate derivatives as progesterone receptor modulators and methods of treating skin disorders | NR5A1, MC1R, CYP17A1 | LMNA 4684/4885CYP3A4 1973/4885GABRA1 1780/4885 |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | OXTR, GNRHR, SHBG | LMNA 1295/4885CYP3A4 467/4885GABRA1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.